A Bronx hospital won a research award to test if scans can predict clot-removal success.
AngioDynamics and The PERT Consortium have awarded Jacobi Hospital investigators with an ALPHA-PE Research Fund grant. The study, led by Dr. Jonathan Alis and Dr. Seth I. Sokol, will examine CT pulmonary angiography radiomics to predict the success of thrombectomy and long-term outcomes for pulmonary embolism patients. This research aims to provide crucial real-world evidence to help physicians make more informed and individualized treatment decisions for PE patients.
A successor's appointment could set the CEO's retirement date at AngioDynamics (ANGO). There's another trigger.
AngioDynamics CEO James C. Clemmer announced his intention to retire by November 30, 2026, or upon the appointment of a successor, with the possibility of monthly extensions by mutual agreement. The company recently amended its fiscal 2026 annual report to include updated XBRL tagging and disclosed performance against cash-incentive targets, showing net sales of $320.2 million against a $312 million target and adjusted EBITDA of $18.2 million versus a $10.5 million target. Executive compensation for fiscal 2026 was largely performance-based, with cash incentive payouts at 180% of target for named executive officers.
Sales reached $320.2 million at AngioDynamics (ANGO). Five executives received cash bonuses.
AngioDynamics reported net sales of $320.2 million for fiscal year 2026, exceeding its $312 million target. As a result, all five named executive officers received annual cash incentive payouts equal to 180% of their target bonuses. The company's CEO, James C. Clemmer, announced his intention to retire by November 30, 2026, or upon the appointment of a successor, and the company has retention agreements in place for other key executives.
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
AngioDynamics, Inc. (NASDAQ: ANGO) announced it will release its financial results for the first quarter of fiscal year 2027 before market open on Thursday, October 8, 2026. The company will also host a conference call at 8:00 AM ET on the same day to discuss these results. Investors can access the webcast and replay through the company's website.
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
AngioDynamics, Inc. (NASDAQ: ANGO) announced it will report its fiscal year 2027 first quarter financial results before market open on Thursday, October 8, 2026. The company's management will host a conference call at 8:00 am ET on the same day to discuss the results, which will also be webcast. A replay of the call will be available until October 15, 2026.
AngioDynamics Xcela Port Lawsuit Alleges Infection, Migration Caused by Defective Catheter
A Delaware woman has filed a product liability lawsuit against AngioDynamics, claiming her Xcela port catheter was defectively designed, migrated, and caused infection. The lawsuit alleges that AngioDynamics failed to warn about the risks of migration, fractures, and infections associated with their port catheters. This case joins hundreds of similar AngioDynamics port catheter lawsuits consolidated in federal court, alleging defective designs and inadequate warnings.
387,188 Shares in AngioDynamics, Inc. $ANGO Bought by Western Standard LLC
Western Standard LLC has acquired 387,188 shares of AngioDynamics, Inc. (NASDAQ:ANGO) for approximately $5.04 million, making it their 17th largest position. AngioDynamics recently beat quarterly earnings expectations, reporting a loss of $0.07 per share on $86.61 million in revenue, exceeding estimates despite remaining unprofitable. Analyst sentiment is mixed, with a consensus "Hold" rating and a price target of $19.50.
AngioDynamics (NASDAQ:ANGO) Reaches New 12-Month High - Still a Buy?
AngioDynamics (NASDAQ:ANGO) has reached a new 52-week high of $16.25, with mixed analyst ratings including "buy" and "strong sell." Despite beating quarterly earnings and revenue estimates, the company remains unprofitable, and an insider recently sold shares. The consensus rating for ANGO is "Hold" with a $19.50 price target.
Angiodynamics, Inc. (UG2) Q3 2023 Earnings Report - Results, Call & Slides
Angiodynamics, Inc. (UG2) reported its Q3 2023 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of -€0.03 against a consensus of >-€0.01, and actual revenue of €69.95M compared to an expected €72.11M, though revenue did show a 9.11% year-over-year growth. An earnings call was held on March 30, 2023, and the next earnings report is estimated for October 1, 2026.
Angiodynamics, Inc. (UG2) Q1 2025 Earnings Report - Results, Call & Slides
Angiodynamics, Inc. (UG2) released its Q1 2025 earnings report, showing an actual EPS of -€0.10, beating the consensus of -€0.13 by +€0.03. However, the company missed revenue expectations, reporting €58.49M against an expected €58.88M, marking a -14.22% year-over-year decline. The earnings call took place on October 3, 2024, and the next earnings date is estimated for October 1, 2026.
AngioDynamics at Canaccord Genuity conference: growth pivot deepens
AngioDynamics discussed its strategic pivot from a legacy catheter business to a high-growth MedTech portfolio at the Canaccord Genuity conference. The company highlighted 18% MedTech revenue growth in fiscal 2026, now comprising 47% of total revenue, and projected 12-15% MedTech growth for fiscal 2027. Key growth drivers include Auryon, mechanical thrombectomy, and NanoKnife, with an ongoing search for a new CEO as Jim Clemmer plans to retire by year-end 2026.
AngioDynamics, Inc. (ANGO) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow
AngioDynamics, Inc. (ANGO) presented a slideshow at Canaccord Genuity's 46th Annual Growth Conference. The article, authored by SA Transcripts, highlights the company's participation in this event. SA Transcripts is responsible for publishing thousands of quarterly earnings call transcripts and other transcript-related projects on Seeking Alpha.
AngioDynamics Port Catheter Lawsuit
Wisner Baum is actively investigating claims against AngioDynamics and Navilyst Medical concerning implantable port catheters due to reported complications like infection, thrombosis, device fracture, and migration. The AngioDynamics Port Catheter MDL, centralized in California, has grown to over 400 pending actions as of July 2026, with bellwether trials anticipated. The lawsuits allege design and manufacturing defects, failure to warn consumers, negligence, and breach of warranties, claiming the polyurethane catheters degrade and release barium sulfate particles, leading to serious health issues.
(ANGO) Price Dynamics and Execution-Aware Positioning
This article from Stock Traders Daily provides an AI-driven analysis of Angiodynamics Inc. (NASDAQ: ANGO), highlighting strong sentiment across all horizons and significant upside potential due to a lack of resistance levels. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for near-term, mid-term, and long-term horizons. The report emphasizes real-time signals, risk management parameters, and advanced AI models for optimizing trading decisions.
AngioDynamics, Inc. (ANGO) stock price, news, quote and history
This article provides comprehensive financial information for AngioDynamics, Inc. (ANGO), including its current stock price, trading activity, key financial metrics, and an overview of its medical technology products. It also features performance comparisons against the S&P 500, earnings trends, analyst ratings, and a list of comparable companies in the medical instruments and supplies industry.
AngioDynamics, Inc. (ANGO) stock price, news, quote and history
This article provides a comprehensive overview of AngioDynamics, Inc. (ANGO), a medical technology company specializing in cardiovascular and cancer treatment products. It details the company's stock performance, key financial metrics, product portfolio, and analyst insights. The stock closed at $15.69, up 3.84%, with a market capitalization of $648.505M.
AngioDynamics SmartPort Infection Lawsuit Alleges Defective Port Caused Sepsis
A Pennsylvania man has filed a lawsuit against AngioDynamics and Navilyst Medical, alleging that a defective SmartPort catheter caused a severe infection and sepsis, necessitating its surgical removal. The complaint claims that defects in the port catheter promoted bacterial growth and that the companies failed to adequately warn about these risks, despite receiving adverse event reports. This lawsuit joins hundreds of others consolidated in federal court concerning alleged defects in AngioDynamics implantable port systems.
ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?
AngioDynamics (ANGO) shares have increased 33.5% in the last three months, outperforming the market and medical sector, driven by growing interest in its Med Tech platforms. While Med Tech revenue growth and products like NanoKnife and Auryon show promise, valuation concerns, tariffs, and a negative earnings outlook temper future upside. The stock currently holds a Zacks Rank #4 (Sell), suggesting caution due to its valuation and execution risks despite operational improvements.
Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
AngioDynamics (ANGO) faces a trade-off between its rapidly expanding Med Tech platforms and persistent margin pressure from tariffs and rising operating costs. While NanoKnife, Auryon, and AlphaVac show strong growth potential and strategic importance, the company's valuation is mixed, and a Zacks Rank #4 (Sell) suggests a cautious approach. The investment case hinges on whether ANGO can achieve profitable scale quickly enough to overcome these financial headwinds.
ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?
AngioDynamics (ANGO) shares have significantly outperformed the market, gaining 33.5% in three months, driven by its shift towards higher-margin Med Tech platforms like NanoKnife and Auryon. While Med Tech growth and product differentiation support the company's momentum, concerns about valuation, tariff impact on earnings conversion, and a Zacks Rank #4 (Sell) signal suggest caution for investors. The article concludes that further upside requires sustained double-digit growth and clearer evidence of operating gains translating into stronger earnings.
Senior Vice President of Regulatory Affairs Warren Nighan Sold A Bunch Of Shares In AngioDynamics
AngioDynamics' Senior Vice President of Regulatory Affairs, Warren Nighan, recently sold US$344k worth of stock, representing 27% of his holding. While other insiders have purchased shares over the past year, this significant sale and a general trend of insider selling raise caution. Despite insiders owning 10% of the company, the net insider activity suggests a lack of strong confidence.
AngioDynamics, Inc. $ANGO Shares Purchased by Lazard Asset Management LLC
Lazard Asset Management LLC significantly increased its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 1,328.2% during the first quarter, now owning 154,578 shares valued at $1.76 million. This comes as AngioDynamics exceeded Q1 earnings expectations, reporting an adjusted loss of $0.07 per share on $86.61 million in revenue, surpassing analyst estimates. Despite mixed analyst ratings, with a consensus "Hold" and a $19.50 price target, institutional investors collectively hold a substantial 89.43% of the company's stock.
Senior Vice President of Regulatory Affairs Warren Nighan Sold A Bunch Of Shares In AngioDynamics
Warren Nighan, Senior Vice President of Regulatory Affairs at AngioDynamics, recently sold US$344k worth of stock, representing 27% of his holding. While insiders did buy some shares in the last year, the overall trend points to more selling than buying. This sale, the largest by an insider in the last year, suggests caution for potential investors.
Segall Bryant & Hamill LLC Trims Stock Position in AngioDynamics, Inc. $ANGO
Segall Bryant & Hamill LLC has reduced its stake in AngioDynamics, Inc. by 19.4%, selling 232,192 shares but still retaining a significant holding valued at $10.98 million. Despite this reduction, other institutional investors like Goldman Sachs and Jane Street Group increased their positions, with institutional investors collectively owning 89.43% of the company. Analyst opinions are mixed, with some upgrading and raising price targets, while Zacks Research downgraded the stock to "strong sell," resulting in a consensus "Hold" rating and a $19.50 target price.
AngioDynamics (NASDAQ: ANGO) insider plans $344K sale of equity awards
An insider at AngioDynamics (NASDAQ: ANGO) plans to sell 23,370 shares of common stock, valued at approximately $344,004.06. This proposed sale involves equity awards, specifically restricted stock from 2020 and performance share units from 2021, and will be conducted through Morgan Stanley Smith Barney LLC. The transaction is scheduled for July 30, 2026.
AngioDynamics (ANGO) SVP Warren Nighan Jr. sells 23,370 shares at $14.72
AngioDynamics Inc. SVP Quality and Regulatory, Warren Nighan Jr., sold 23,370 shares of the company's common stock on July 30, 2026, at a weighted average price of $14.72 per share. This transaction was not conducted under a Rule 10b5-1 trading plan. Following the sale, Nighan Jr. directly holds 64,745 shares of AngioDynamics.
AngioDynamics (ANGO) SVP Warren Nighan Sells 23,370 Shares
Warren Nighan, SVP of Quality and Regulatory at AngioDynamics (ANGO), sold 23,370 shares for approximately $344,006. This transaction occurred on July 30, 2026, and leaves him with 64,745 shares. While the stock is deemed "Significantly Overvalued" by GuruFocus's GF Value model, institutional investors (gurus) show net-positive sentiment, with 5 of 6 increasing their positions.
Form 4 AngioDynamics Inc For: 31 July By Investing.com
This article reports on a Form 4 filing for AngioDynamics Inc. for July 31st. It provides various financial market data, including indices, commodities, bonds, and shares, along with trending stocks and investment strategy suggestions. The core content is the announcement of the Form 4 filing.
Angiodynamics SVP Warren Nighan Jr sells $344,006 in stock
Warren Nighan Jr., Senior Vice President at AngioDynamics Inc., sold 23,370 shares of company stock for a total of $344,006. This transaction occurred as the stock trades near its 52-week high after a 67% gain, with InvestingPro analysis suggesting it is overvalued. Despite the insider sale, AngioDynamics recently reported strong fiscal Q4 2026 net sales and positive analyst price target revisions, citing growth in the Med Tech segment and a favorable outlook for fiscal 2027.
Angiodynamics SVP Warren Nighan Jr sells $344,006 in stock
AngioDynamics Inc.'s Senior Vice President, Warren Nighan Jr., sold 23,370 shares of company stock for $344,006. This sale occurred as the stock trades near its 52-week high, having gained 67% over the past year. The company recently reported strong fiscal fourth-quarter results, exceeding analyst expectations, and several analysts have raised their price targets with "Buy" ratings.
AngioDynamics Inc (ANGO) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of AngioDynamics Inc (ANGO), stating its current valuation score is 7.33, ranking 152 out of 199 in the Healthcare Equipment & Supplies industry. The company's P/E ratio is -19.48, which is significantly below its recent high. It also notes that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
AngioDynamics Inc (ANGO) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for AngioDynamics Inc (ANGO), highlighting its current risk score, industry ranking, and beta value. It details the stock's volatility, maximum drawdown, and return metrics over various periods, emphasizing its tendency to underperform in up-trending markets and experience smaller declines in down-trending markets. The assessment also includes liquidity measures like average turnover rate.
ANGO|AngioDynamics Inc|Price:14.630|Chg%:+0.290
This article provides a comprehensive stock analysis of AngioDynamics Inc (ANGO), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. It notes high institutional ownership and a recent "Buy" rating from analysts with an expected upward trend in stock price. Despite good market performance, technical indicators suggest the stock is currently trading sideways, suitable for range-bound swing trading.
AngioDynamics Number of Employees 2026 | Employee Count & Headcount Data
AngioDynamics, Inc. (ANGO) has 627 employees worldwide as of March 2026, marking a 2.8% decline since 2023 but a 0.1% increase year-over-year. The company is actively hiring, with 58 job postings in 2026, a 39.2% increase from 2025. Its workforce is concentrated in North America, and the average salary is $100,967.
AngioDynamics Inc (ANGO) Institutional Confidence
AngioDynamics Inc (ANGO) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is 93.94%, a decrease of 11.97% quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 3.06 million shares, despite a slight decrease in his holdings.
Live webcast set for AngioDynamics' Aug. 11 presentation
AngioDynamics, Inc. announced its management team will participate in upcoming investor conferences, including the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 10, 2026, and Canaccord Genuity's 46th Annual Growth Conference on August 11, 2026. A live webcast of the Canaccord Genuity presentation will be available on the company's website. AngioDynamics is a medical technology company focusing on vascular systems, cancer treatment, and patient quality of life.
AngioDynamics Inc (ANGO) Balance Sheet
This article provides key balance sheet information for AngioDynamics Inc (ANGO), including quarterly and annual data for various assets, liabilities, and shareholders' equity components. It allows users to evaluate the company's financial health, analyze fundamentals, and calculate key financial ratios. The data highlights recent trends in cash, receivables, inventory, and total assets, as well as different categories of liabilities and equity.
AngioDynamics Inc (ANGO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for AngioDynamics Inc (ANGO) as of April 6. It shows that the majority of its revenue (85.79%, or $67.28M) comes from the United States, with 14.21% ($11.14M) from international regions. The article notes that relevant data for business segments have not yet been disclosed by the company.
AngioDynamics Inc
AngioDynamics Inc (ANGO) is a medical technology company focused on vascular health and cancer treatment. The company designs, manufactures, and sells devices for vascular access, peripheral vascular disease, oncology, and surgical settings. Its product categories include oncology, venous therapies, vascular interventions, and ports, utilized in minimally invasive, image-guided procedures.
AngioDynamics, Inc. Revenue Breakdown – NASDAQ:ANGO
AngioDynamics, Inc. (NASDAQ: ANGO) generated a total revenue of $320.17 million USD last year. The Med Device segment was the top-performing segment, contributing $170.22 million USD, an increase from the previous year. The United States was the largest geographical contributor, accounting for $274.92 million USD of the total revenue.
AngioDynamics (NASDAQ: ANGO) CEO settles performance share grant
AngioDynamics (NASDAQ: ANGO) CEO James C. Clemmer settled a performance share grant from 2023, receiving 52,358 shares of Common Stock. The original grant of 184,361 units was based on multi-year performance metrics, with the remaining units forfeited. To cover tax withholding obligations, 26,728 shares were disposed of at $13.82 per share.
AngioDynamics Inc (ANGO) CFO performance shares vest, tax withheld
AngioDynamics Inc. CFO Stephen A. Trowbridge received 16,296 shares of common stock from the vesting of performance share units, which were part of a target grant of 57,381 units on July 19, 2023. The shares vested based on performance metrics and relative total shareholder return, with the remaining units forfeited. To cover tax withholding obligations, 8,319 shares were sold at $13.82 per share.
AngioDynamics (ANGO) SVP receives shares from PSU vesting, with tax withholding
Chad Thomas Campbell, SVP/GM Vascular Access at AngioDynamics (ANGO), received 6,466 shares of common stock from the vesting of performance share units, which were originally granted on July 19, 2023. To cover tax withholding obligations, 2,330 shares were disposed of at $13.82 per share. The original target grant was 22,768 performance share units, with earning potential tied to performance metrics and total shareholder return.
Form 4 AngioDynamics Inc For: 24 July By Investing.com
This article announces the filing of Form 4 for AngioDynamics Inc. on July 24, indicating insider transaction activity. It is a brief news item from Investing.com, providing basic information about the filing and the company's stock performance.
AngioDynamics (NASDAQ: ANGO) executive settles 20,052 performance units
Warren Nighan Jr., SVP Quality and Regulatory at AngioDynamics (NASDAQ: ANGO), had a 2023 performance share unit grant settle, resulting in 5,694 shares of common stock being issued from a target of 20,052 units. The remaining units were forfeited, and 1,671 shares were withheld to cover tax obligations. This transaction reflects insider activity as detailed in a Form 4 filing.
AngioDynamics Inc. (ANGO) SVP receives 8,047 shares, 4,506 withheld for tax
AngioDynamics Inc.'s SVP International, Laura Piccinini, received 8,047 common shares from the vesting of performance share units granted in July 2023. Of these, 4,506 shares were withheld for tax obligations at $13.82 per share, and the remaining 20,289 units from the original grant were forfeited due to performance metrics. The transaction resulted in a net acquisition of 3,541 shares for Piccinini, bringing her direct common stock holdings to 81,929 shares.
AngioDynamics Inc. (ANGO) awards 17,966 RSUs and performance rights
AngioDynamics Inc. (ANGO) has granted its SVP of Quality and Regulatory, Warren Nighan Jr., 17,966 restricted stock units (RSUs) and 17,966 performance rights. The RSUs will vest in four equal annual installments from July 2027 to 2030, while the performance rights are tied to a three-year relative total shareholder return performance period. Following these awards, Nighan Jr. directly holds 84,092 shares of common stock.
AngioDynamics (ANGO) director granted 11,887 immediately vested RSUs
AngioDynamics Inc. director Auen Eileen O'Shea was granted 11,887 restricted stock units (RSUs) as part of her regular annual compensation. These RSUs, which represent 11,887 shares of common stock, vested immediately, increasing her direct holdings to 116,605 shares. The transaction, filed as a Form 4, indicates a neutral impact and sentiment.
AngioDynamics (ANGO) director receives 11,887-share stock award
AngioDynamics Inc. (ANGO) director Karen A. Licitra was granted 11,887 shares of common stock on July 15, 2026, as regular annual compensation for her board service. These restricted stock units immediately vested upon grant, increasing her direct holdings to 102,322 shares. The transaction, reported in a Form 4 filing, indicates no cash was paid for this award.
RSU grant lifts AngioDynamics Inc. (ANGO) director to 116,921 shares
AngioDynamics Inc. director Jan Stern Reed was granted 11,887 restricted stock units (RSUs) on July 15, 2026, as regular annual compensation for board service. These RSUs immediately vested, increasing Reed's direct holdings to 116,921 common shares. The transaction, reported at $0.00 per share, was detailed in an SEC Form 4 filing.
